Scancell Share Discussion Threads

[sarkasm] 08/1/2019 14:41

Many many years ago, whilst on holiday in the Greek islands, I sat in an afternoon, at the bar of my 'up-market' hotel...

lOZAN

Strange story

but why mention

up market hotel


was it an integeral part of the plot or just adding colour to the scene

anyways a nice story to start 2019

cheers and have a good one

[bermudashorts] 07/1/2019 15:13

Not sure if above link is working - this should take you to article

[bermudashorts] 07/1/2019 14:26

Nice article highlighting the different ways the CRUK Commercial Partnerships Team are working to accelerate new treatments - impressive stuff. Have quoted a couple of bits of interest to Scancell.

' Through its Clinical Development Partnerships scheme, CRUK takes promising assets into clinical development when companies are unable to do so themselves. “[This scheme] is about being able to identify deprioritised agents that the company doesn’t have the bandwidth to progress, but which have potential patient benefit,” explains Masterson. “In those situations, we are able to bring [the agents] in, our Phase 1 Clinical Trial Unit runs the trial, and the company then has the option to take those trial results forward themselves. If they elect not to take up the option, we pick up the rights to that asset and are able to drive forward the development ourselves with a revenue share back to the company.”'

'Going forward, the organisation plans to expand its international footprint in cancer research and move towards a more global outlook. This is reflected in its Grand Challenge scheme, which provides up to £20 million of funding for international, multidisciplinary teams harnessing novel methods to take on the biggest challenges in cancer research. The 2017-2018 Grand Challenges span: tissue specificity; tumour vaccinology; treatment regimens; dormancy; lethal vs non-lethal; artificial intelligence; microbiota; cancer causes. “This is a good example of where we are addressing the big unmet need questions in oncology on an international playing field, and bringing the right people together to get those questions answered,” says Masterson.'

hTTtps://www.lsxleaders.com/blog/cancer-research-uk-partnering-to-accelerate-cancer-research-translation-and-commercialisation?utm_campaign=Partner%20content&utm_content=82039807&utm_medium=social&utm_source=twitter&hss_channel=tw-2435194891

[gooosed] 07/1/2019 14:06

First link posted by vascular on LSE bb with ref to "HOLY GRAIL"



& seems to be fit with



&

[bermudashorts] 04/1/2019 13:44

gooosed no problem - will be interesting to see how things play out for BioNtech, they've certainly got some impressive deals under their belt.

[gooosed] 04/1/2019 13:07

Bs - apologies, I have duplicated some of your post.

Interesting to see if BioNTech follow through with an IPO in 2019.

[gooosed] 04/1/2019 12:59

Scancells CEO "we expect to see some of the results of that coming out towards the end of this year" when referring to the research partnership with BioNTech back in January last year (from 03:15)

[bermudashorts] 04/1/2019 12:58

Couple of interesting announcements from BioNtech today

[waldron] 03/1/2019 15:43

Breath test to detect multiple cancers early begins large trial

Tara John, CNN

Updated 1343 GMT (2143 HKT) January 3, 2019
A two-year trial into a clinical device, called the Breath Biopsy, will see if exhaled airborne molecules can be useful for cancer detection.
A two-year trial into a clinical device, called the Breath Biopsy, will see if exhaled airborne molecules can be useful for cancer detection.

(CNN)A breathalyzer designed to detect multiple cancers early is being tested in the UK.
Several illnesses are known to create signature smells from the body, including typhoid fever reported to smell like baked bread and the aroma of acetone, said to be similar to rotten apples, on the breath of diabetics. Recent research has also shown that a person's breath could also indicate the presence of cancer.
To test this theory, Cancer Research UK have launched a two-year trial into a clinical device, called the Breath Biopsy, to find out if exhaled airborne molecules can be useful for cancer detection.

How dogs sniff out diabetes on your breath
How dogs sniff out diabetes on your breath
In the body's normal metabolic processes, molecules called volatile organic compounds (VOCs) are produced. It's thought that cancer can create a different pattern of VOCs, which researchers hope to identify using the device. "Our goal is, can we spot these subtle differences?," Billy Boyle, co-founder and CEO at Owlstone Medical which developed the device, told CNN.
The trial, which is being run by the Cancer Research UK Cambridge Centre, is recruiting up to 1,500 participants, including healthy people to act as a control group.
Patients with stomach and esophageal cancers will initially be asked to try the test, before expanding to patients with prostate, kidney, bladder, liver and pancreatic cancers.
Participants will be asked to breathe into the device for 10 minutes to provide a sample, which will be analyzed by Owlstone Medical's laboratory in Cambridge.
The idea is to identify if cancer signals are similar or different and how early any signals could be picked up. If some people go on to develop cancer, their samples will be compared to those who don't develop the disease.
Late diagnosis
"We urgently need to develop new tools, like this breath test, which could help to detect and diagnose cancer earlier, giving patients the best chance of surviving their disease," Professor Rebecca Fitzgerald, lead trial investigator at the Cancer Research UK Cambridge Centre, said in a statement.
Almost half of cancers are diagnosed at a late stage in England, according to Cancer Research UK. Some of the reasons are due to patients' fears of invasive tests, a lack of knowledge of cancer signs and symptoms, and the lack of early detection tests for certain cancers.
Rabbit gene turns houseplant into air detoxifier
Rabbit gene turns houseplant into air detoxifier
Early detection can be a matter of life and death added Boyle, who added that around 85% of people with lung cancer are diagnosed at a late stage, "and they will die in one or two years [because] by the time doctors diagnose it, it is too late."
There are more than 360,000 new cancer cases in the UK every year, according to Cancer Research UK. Globally, an estimated 18.1 million new cases of cancer were reported in 2018, according to the World Health Organization.
The need for trials
In 2017, researchers told CNN they had developed a device which -- using nanorays to analyze breath -- can identify Parkinson's disease, various cancers, kidney failure, multiple sclerosis and Crohn's disease with 86% accuracy.
But the experimental technology analyzing breath had a number of issues it had to address: including the problem of storing breath that is not immediately analyzed.
Boyle agreed that it is hard to "capture, store, and transport" breath, but added that the Breath Biopsy device has been developed to solve those issues. He said the device captures chemicals using a cartridge, which "acts like a sponge," and it is then transported to a lab where it is analyzed.
If the trial turns into a success, both Boyle and Cancer Research hope the breath biopsies will be used in doctors' practices to figure out whether patients should be referred for further diagnostic tests.
"Through this clinical trial we hope to find signatures in breath needed to detect cancers earlier -- it's the crucial next step in developing this technology," Fitzgerald said in a statement.

Today's widespread interest in breath analysis stems from the relatively recent discovery -- within the past 20 years or so -- that nitric oxide, a common pollutant, works as a signaling molecule in the cardiovascular system, Terence Risby, professor emeritus at the Johns Hopkins University Bloomberg School of Public Health, told CNN in 2017. The three scientists who made the discovery won a Nobel Prize for their efforts in 1998.
The theory behind the technology is that each of us has a unique chemical "fingerprint." Each disease also has a particular chemical signature, which can be detected on our breath.

CNN's Susan Scutti contributed to this report.

[oldnotwise] 03/1/2019 15:21

Terror
Fair comment, all positive and pertinant points, none of which I disagree with, but I wonder whether or not the market's ready to rerate us when it seems that there'll still be a not insignificant delay to the first commercials.
That said, I do hope you're right and that the market perception and realisation that the (potential of the)IP is massively out of Kilter with the share price will become (at least) the prinmary driver for the next phase of the Company's commercial (hence positive cashflow)development.
Once the market fets to grips with that I'm really, really optimistic that shareholders will start to reap the benefits that the IP offers.
Maybe I've been a bit too pessimistic, but if we have to wait a bit longer so be it...If not, I'm very happy.
AIMO
ATB

[terror] 03/1/2019 14:33

Old - I see a number of benefits:

1. Increased knowledge
2. Publicity
3. Will probably lower Scancell's ongoing costs
4. Improves personal Cancer Vaccines and therefore benefits Scancell end products

[gooosed] 03/1/2019 13:33

Conferences being attended by Lindy/Scancell:

[oldnotwise] 03/1/2019 13:31

Terror
In what way? I'm not convinced that it'll make a great deal of difference to the share price (but I hope it does)!
ATB

[terror] 03/1/2019 13:27

Grand Challenge result announced on 23 January.

Should be an interesting lead up to that.

[oldnotwise] 03/1/2019 12:56

I see there's some (remote) comment about Ichor again.
It seems that the points made some weeks ago that the FDA is likely raising points regarding the Trigrid 2 peculiar to Scancell's proposed trial seems to me to make it a Scancell "issue" (requiring their comments) rather than an Ichor one.
So to say that any delay is an Ichor problem is to my mind completely missing the point.
Anyway, i think this BB understands the issue rather more clearly from points already made, rather than having to start all over again with (IMO) an inappropriate comment.
AIMO
ATB

[gooosed] 01/1/2019 10:55

Bs - Thanks for taking the time to transcribe what was said. Hmmmm - here's hoping Chiplin's one or two alternatives work out a bit better than his plan A. There must be a reason for maintaining a remote Chair & US based BoD members.

[bermudashorts] 31/12/2018 14:18

goosed - following your post I've had another listen to exactly what CH said at the AGM when he was asked about funding. Transcription below:-

"Overheads are around £350,000 per month. I don't think that will increase appreciably over the next period but what we have to pay for now is obviously the clinical trials once we get up and running. So obviously our external costs in terms of orchestrating these clinical trials will increase our cash flow but that's why we raised the money, to direct towards the execution of those clinical studies. So we have enough capital to initiate and hopefully complete the SCIB1 study so that will take us through into 2020 and to initiate the activities towards the Modi1 study. At this point in time we have no plans to raise additional capital."

Make of that what you will. Earlier JC did also say that they were looking at one or two alternatives to dilutive funding.

[gooosed] 31/12/2018 12:45

Thanks Oldnotwise & wigwammer.

Best wishes to all for 2019 ! !

[wigwammer] 31/12/2018 12:28

My overall impression from the Q&A is they are hoping for some cash inflow from the BioNTech TCR project in 2019. They described BioNtech as a rapidly developing company but one that still has to live within a budget. Hence, they recognise the need to partner earlier and potentially pay a smaller amount than larger pharma who are generally happy to see a project derisked before paying a more significant premium. I would have to listen to the recording again, but I recall a figure of £10m being mentioned - not as exciting as the £30m+ some have touted but enough to see them complete the studies without dilution.

[wigwammer] 31/12/2018 12:23

Goosed - the question I think you refer to was "now the trial is delayed will you have sufficient funds to complete both studies?" (it was the last question asked). CH suggested that they could shuffle costs, and that up to the delayed trial start, they would be spending less pm, hence the funds may be sufficient. I believe Chiplin also added that they have "a few ideas" regarding non dilutive funding.

[oldnotwise] 31/12/2018 12:19

Gooosed
I can't recall hearing the bit about not raising, but then I wasn't listening for it, because I certainly wouldn't expect CH to be saying there was on the basis that that sets a target for the market. I'd rather take the info from Trinity and then hope the call was never made rather than the other way round.
Anyway, if the share price were to start a rerate and no cash was raised - although dilutary - new word?- I'd be even more convinced that we were close to a commercial deal.... But G*d help the BOD if they wasted a chance to raise at a significantly higher share price ... Bit of insurance maybe....
So on balance, I'd go for a cash raising of some description IDC, but if not..... well, I'm even happier.
So as we hurtle towards Year End I'd like to wish everyone a VERY Happy New Year and let's hope that includes the Scancell SP!!!!
All the Best to Everyone...
:-)

[gooosed] 31/12/2018 11:13

Bs - I've listened to the AGM recording a couple of times now & I seem to remember someone asking directly if funds would need to be raised next year,2019. If memory serves (always room for doubt on that one) the answer given by Holloway was that they wouldn't - yet Trinity Delta report sites the need for £12m odd. How to square the circle . . . .

[drdobson1] 31/12/2018 10:12

Thank you Barmooda.
Being an Astutie I have a clear aim to CONteract the attempted CONtrol of the CON merchants and the Der Leader Oies and Midinformation.
You are respected poster who only wants TRUTH and Honesty totally in CONtrast to baNANA and his trHYPE Gang.

[bermudashorts] 31/12/2018 09:55

Yep, they had £10m in the bank back in April. Trinity Delta report estimates around £4m by this Y/E (April). So not true to say that they have approaching £10m in the bank or that the Grand Challenge will fund 2 or 3 years research.